Neurology
Commentary
What to expect in the new concussion guidelines
“Right now, at least at the concussion conference I went to and in the upcoming consensus statement, they will not comment on a specific sport.”...
From the Journals
AHA urges action against racial inequities in stroke care
Insufficient research attention has been paid to reducing inequities in rehabilitation, recovery, and social reintegration, the writing group says...
News
Deep sleep may mitigate the impact of Alzheimer’s pathology
“Think of deep sleep almost like a life raft that keeps memory afloat, rather than memory getting dragged down by the weight of Alzheimer’s...
News
Parkinson’s in Marines linked to toxic drinking water at Camp Lejeune
“This is by far the largest study to look at the association of TCE and PD and the evidence is pretty strong.”
From the Journals
Rheumatoid arthritis linked to increased Parkinson’s risk
“If patients with rheumatoid arthritis begin exhibiting motor symptoms such as muscle rigidity, tremors, or slowed movement, it is imperative that...
News
FDA approves first drug to treat Alzheimer’s agitation
“Agitation is one of the most common and challenging aspects of care among patients with dementia due to Alzheimer’s disease.”
From the Journals
Hearing aids are a ‘powerful’ tool for reducing dementia risk
“The evidence is building that hearing loss may be the most impactful modifiable risk factor for dementia in mid-life.”
Guidelines
AHA backs screening for cognitive impairment after stroke
Cognitive impairment is common after a stroke; screening may help detect it early and allow appropriate multidisciplinary care, AHA says.
Conference Coverage
Head-to-head comparison of migraine meds reveals top options
“To the best of our knowledge, this is the first study that simultaneously compared multiple acute migraine medications using a Big Data analysis...
News
FDA expands atogepant approval to include chronic migraine
The approval makes atogepant the first, and only, oral CGRP receptor antagonist approved to prevent migraine across frequencies, including...
Conference Coverage
Donanemab bests aducanumab in head-to-head Alzheimer’s trial
Nearly 40% of patients treated with donanemab had amyloid clearance at 6 months compared with less than 2% of those who received aducanumab.